Xenetic Biosciences has a quick ratio of 11.70. It generally indicates good short-term financial strength.
The historical rank and industry rank for Xenetic Biosciences's Quick Ratio or its related term are showing as below:
XBIO'
s Quick Ratio Range Over the Past 10 Years
Min: 0.13 Med: 4.2 Max: 18.36
Current: 11.7
During the past 13 years, Xenetic Biosciences's highest Quick Ratio was 18.36. The lowest was 0.13. And the median was 4.20.
XBIO's Quick Ratio is ranked better than 83.38% of 1546
companies
in the Biotechnology industry
Industry Median: 3.595
vs XBIO: 11.70
Xenetic Biosciences Quick Ratio Historical Data
The historical data trend for Xenetic Biosciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Xenetic Biosciences's Quick Ratio
For the Biotechnology subindustry, Xenetic Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenetic Biosciences's Quick Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Xenetic Biosciences's Quick Ratio falls into.
Xenetic Biosciences Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Xenetic Biosciences's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenetic Biosciences (NAS:XBIO) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Xenetic Biosciences Quick Ratio Related Terms
Thank you for viewing the detailed overview of Xenetic Biosciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Xenetic Biosciences (Xenetic Biosciences) Business Description
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XBIO has been successfully added to your 